Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘Cell Therapeutics Inc (CTIC)’

Incyte Corporation (NASDAQ:INCY)

Incyte Corporation (INCY), Gilead Sciences, Inc. (GILD): Pop-Worthy Data, Incyte, but Let’s See More

The phase 2 data that Incyte Corporation (NASDAQ:INCY) presented on Wednesday was downright stellar. For a subgroup of the patients, the hazard ratio......(read more)
American Capital Agency Corp. (NASDAQ:AGNC)

Real Estate News: Annaly Capital Management, Inc. (NLY) New CFO, American Capital Agency Corp. (AGNC)’s Put Options, American Capital Ltd. (ACAS) Percentage Change

Editor’s Note: Annaly Capital Management, Inc. (NYSE:NLY), American Capital Agency Corp. (NASDAQ:AGNC), American Capital Ltd. (NASDAQ:ACAS) CFO......(read more)
Sprint Nextel Corporation (NYSE:S)

Sprint Nextel Corporation (S), Cell Therapeutics Inc (CTIC): 5 Companies That Haven’t Earned Their Keep

In order to become a successful investor, it takes a love for finance, quite a bit of discipline, and a long-term mind-set. Another important factor that......(read more)
Oncothyreon Inc (USA) (NASDAQ:ONTY)

Oncothyreon Inc (USA) (ONTY): Are Hedge Funds Right About This Stock?

Oncothyreon Inc (USA) (NASDAQ:ONTY) was in 9 hedge funds’ portfolio at the end of the fourth quarter of 2012. ONTY shareholders have witnessed a......(read more)

Sarepta Therapeutics Inc (SRPT): FDA Says, “Call Me Maybe”

A lot has been written this week — at The Fool and elsewhere — about Sarepta Therapeutics Inc (NASDAQ:SRPT)‘ update on its meeting......(read more)